Metabolic & weight
Tirzepatide
A dual agonist at the GIP and GLP-1 receptors.
About
Tirzepatide is a synthetic peptide that acts at two incretin receptors rather than one. It has been through extensive clinical development and holds approved indications in a number of jurisdictions. It is subject to an in-force compound patent in Mexico, and COFEPRIS has issued a health alert regarding products containing tirzepatide sold without sanitary registration. This compound is handled by individual professional consultation only.
Mechanism
The molecule is an agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. Dual agonism is the principal point of mechanistic interest: published work describes the combination as producing effects on insulin secretion and appetite regulation that differ from GLP-1 receptor agonism alone. A C20 fatty diacid moiety promotes albumin binding and extends half-life.
What research has examined
Tirzepatide has been evaluated in randomised trials examining glycaemic control and body weight.
This page is reference information, not medical advice and not an offer of sale. Tirzepatide is handled through individual professional consultation, and any decision is made together with a licensed healthcare professional who reviews your case. See our Terms for the full notice.